8-K current report · filed Nov 5, 2026

Organogenesis Holdings Inc. (ORGO) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1ORGO overview

Short answer

Organogenesis Holdings Inc. (ORGO) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal third-quarter results ended September 30, 2026 announced by Organogenesis Holdings.

Organogenesis Holdings Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal third-quarter results ended September 30, 2026 announced by Organogenesis Holdings
  • Full financial results and management commentary available in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $45.5M, down 70%, with Advanced Wound Care down 73% to $38.2M
  • Gross margin fell to 52% from 76%, signaling severe operating deleverage despite operating expenses down 42%
  • Adjusted EBITDA loss $22.4M versus $30.1M income, confirming deterioration beyond one-time charges
  • Cash, cash equivalents and restricted cash fell to $26.9M from $94.3M, increasing financing and liquidity risk
  • 2026 revenue outlook cut to $179.4M-$200.0M, a 65%-68% decline versus 2025 revenue of $564.2M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Organogenesis Holdings Inc. 8-K filings

Get the next ORGO 8-K as it lands

Follow ORGO for push alerts, or ask the research agent what this filing means.